An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs ACH 4471 (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 08 Aug 2018 According to an Achillion Pharmaceuticals media release, the company expect to provide interim data and a strategic update in December 2018.
- 30 May 2018 Status changed from not yet recruiting to recruiting.
- 22 Feb 2018 According to an Achillion media release, interim data from this study is expected in fourth quarter 2018.